Integrated Biopharma, Inc. INBP
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -3.08% | -10.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.08% | -10.40% | |||
| Cost of Revenue | -5.92% | -7.71% | |||
| Gross Profit | 110.14% | -1,051.72% | |||
| SG&A Expenses | 10.88% | -14.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.71% | -8.22% | |||
| Operating Income | 19.91% | -18.71% | |||
| Income Before Tax | 17.87% | -18.42% | |||
| Income Tax Expenses | 360.61% | -76.79% | |||
| Earnings from Continuing Operations | -63.20% | -9.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -63.20% | -9.84% | |||
| EBIT | 19.91% | -18.71% | |||
| EBITDA | 21.44% | -21.65% | |||
| EPS Basic | -63.57% | -9.80% | |||
| Normalized Basic EPS | 21.05% | -18.75% | |||
| EPS Diluted | -46.67% | 0.00% | |||
| Normalized Diluted EPS | 21.05% | -18.75% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||